Amgen announced that Wezlana™ (ustekinumab injection) and Wezlana™ (ustekinumab for injection, solution for intravenous infusion), biosimilar to Janssen’s Stelara®, is now available in Canada. Wezlana™ is the first biosimilar to be approved by Health Canada for all Stelara® indications, but the second ustekinumab Canadian launch following the launch of the first ustekinumab biosimilar (Jamteki™) in Canada by JAMP Pharma on 1 March 2024.
Jamteki™ was developed by Alvotech and was approved by Health Canada in November 2023.